Estradiol benzoate/testosterone propionate
 | |
 | |
| Combination of | |
|---|---|
| Estradiol benzoate | Estrogen |
| Testosterone propionate | Androgen; Anabolic steroid |
| Clinical data | |
| Trade names | Bothermon |
| Other names | EB/TP |
| Routes of administration | Intramuscular injection |
| Identifiers | |
| CAS Number | |
Estradiol benzoate/testosterone propionate (EB/TP), sold under the brand name Bothermon, is an injectable combination medication of estradiol benzoate (EB), an estrogen, and testosterone propionate (TP), an androgen/anabolic steroid.[1][2][3][4][5] It contains 0.24 mg/mL EB and 4.76 mg/mL TP in oil solution in each ampoule and is administered by intramuscular injection.[1] The medication was marketed in Japan by 1953[4] and remains available in this country today.[5]
| Route | Medication | Major brand names | Form | Dosage |
|---|---|---|---|---|
| Oral | Testosterone undecanoate | Andriol, Jatenzo | Capsule | 40–80 mg 1x/1–2 days |
| Methyltestosterone | Metandren, Estratest | Tablet | 0.5–10 mg/day | |
| Fluoxymesterone | Halotestin | Tablet | 1–2.5 mg 1x/1–2 days | |
| Normethandronea | Ginecoside | Tablet | 5 mg/day | |
| Tibolone | Livial | Tablet | 1.25–2.5 mg/day | |
| Prasterone (DHEA)b | – | Tablet | 10–100 mg/day | |
| Sublingual | Methyltestosterone | Metandren | Tablet | 0.25 mg/day |
| Transdermal | Testosterone | Intrinsa | Patch | 150–300 μg/day |
| AndroGel | Gel, cream | 1–10 mg/day | ||
| Vaginal | Prasterone (DHEA) | Intrarosa | Insert | 6.5 mg/day |
| Injection | Testosterone propionatea | Testoviron | Oil solution | 25 mg 1x/1–2 weeks |
| Testosterone enanthate | Delatestryl, Primodian Depot | Oil solution | 25–100 mg 1x/4–6 weeks | |
| Testosterone cypionate | Depo-Testosterone, Depo-Testadiol | Oil solution | 25–100 mg 1x/4–6 weeks | |
| Testosterone isobutyratea | Femandren M, Folivirin | Aqueous suspension | 25–50 mg 1x/4–6 weeks | |
| Mixed testosterone esters | Climacterona | Oil solution | 150 mg 1x/4–8 weeks | |
| Omnadren, Sustanon | Oil solution | 50–100 mg 1x/4–6 weeks | ||
| Nandrolone decanoate | Deca-Durabolin | Oil solution | 25–50 mg 1x/6–12 weeks | |
| Prasterone enanthatea | Gynodian Depot | Oil solution | 200 mg 1x/4–6 weeks | |
| Implant | Testosterone | Testopel | Pellet | 50–100 mg 1x/3–6 months |
| Notes: Premenopausal women produce about 230 ± 70 μg testosterone per day (6.4 ± 2.0 mg testosterone per 4 weeks), with a range of 130 to 330 μg per day (3.6–9.2 mg per 4 weeks). Footnotes: a = Mostly discontinued or unavailable. b = Over-the-counter. Sources: See template. | ||||
See also
References
- 1 2 伴一郎, & 杉山陽一. (1956). 男性ホルモンと黄体ホルモンとの混合製剤 Testoluton の使用成績. [Testoluton (Schering), A Combined Preparation of Testosterone Propionate and Progesterone Applied for Clinical Use] 産婦人科の進歩, 8(2), 100-103. https://www.jstage.jst.go.jp/article/sanpunosinpo1949/8/2/8_2_100/_pdf
- ↑ 村上清. (1959). 産科婦人科的ホルモン療法の概況 (本邦). [Overview of obstetrics and gynecology hormone therapy (in Japan).] 産婦人科の進歩, 11(Special), 6-30. https://www.jstage.jst.go.jp/article/sanpunosinpo1949/11/Special/11_Special_6/_pdf
- ↑ 山村博三. (1956). 機能性子宮出血の性ホルモン療法. [Sex hormone therapy for functional uterine bleeding.] 関西医科大学雑誌, 8(4), 293-299. https://www.jstage.jst.go.jp/article/jkmu1956/8/4/8_293/_pdf
- 1 2 植田安雄, & 辻井翠. (1953). 月経困難症に対する Androgenestrogen 混合剤 Bothermon の応用 (治療成績). [Application of Androgenestrogen Bothermon for dysmenorrhea (treatment results).] ホルモンと臨床, 1(4), 333-337. https://ci.nii.ac.jp/naid/40018513715/
- 1 2 https://www.drugs.com/international/bothermon.html
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.